Clinical Trial Update: SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant therapy combining SBRT, chemotherapy, and AK104 for triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Hubei Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING